Paysign, Inc.PAYS

Paysign, Inc. is a Nevada corporation that sells payment solutions to pharmaceutical manufacturers, corporate clients, and digital banking users, according to the company’s product pages. Its offerings include patient affordability programs for prescription drugs, corporate disbursement services, and digital banking accounts under the Paysign Premier brand. These products are promoted as end-to-end solutions designed to eliminate financial barriers and enhance customer experience, but the balance sheet for the quarter to March 2026 tells a quieter story.

For the three months ended 31 March 2026, Paysign reported revenue of $28.0 million, net income of $5.4 million, and diluted earnings per share of $0.09 on 61.0 million shares. Operating income stood at $6.7 million, while operating cash flow clocked in at $18.8 million-impressive on paper, less so when set against total assets of $312.7 million and liabilities of $257.7 million. The company’s net cash provided by operating activities was $18.8 million, while capital expenditures were a modest $266,465, signalling little heavy lifting on the capex front. The equity cushion-$55.0 million-is thin relative to the liabilities stack, leaving the balance sheet looking more like a fragile raft on choppy water than a sturdy vessel. (source: 10-Q, period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/1496443/000168316826005583/xslF345X06/ownership.xml)

Paysign’s product pages describe partnerships with leading pharmaceutical and hub services companies to deliver patient affordability solutions and corporate disbursement services. The company’s digital banking page pitches Paysign Premier as an innovative account “designed with modern businesses in mind.” These are real products marketed to real customer segments, but the financial evidence suggests the commercial traction has yet to translate into balance-sheet muscle. The company’s website and product pages provide colour on the offering-pharmaceutical affordability, corporate disbursements, and digital banking-but do not disclose customer counts, contract lengths, renewal rates, or revenue concentration. (source: Pharmaceutical Services, https://paysign.com/solutions/pharmaceutical-services/; Digital Banking Solutions, https://paysign.com/solutions/digital-banking-solutions/)

The latest 10-Q period ending 31 March 2026 is the most recent filed financial evidence available. It shows revenue of $28.0 million, net income of $5.4 million, diluted EPS of $0.09, and operating cash flow of $18.8 million. Operating income was $6.7 million, with assets of $312.7 million, liabilities of $257.7 million, and stockholders’ equity of $55.0 million. Diluted weighted average shares outstanding were 61.0 million. Capital expenditures were $266,465, and net cash provided by operating activities was $18.8 million. These figures are sourced directly from the 10-Q filing and are not subject to forward-looking statements or management guidance in this file. (source: 10-Q, period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/1496443/000168316826005197/xslF345X06/ownership.xml)

The balance sheet’s liabilities-to-assets ratio sits at roughly 82%, while equity covers just under 18% of assets. Operating cash flow of $18.8 million is healthy relative to net income, but the company’s equity base limits financial flexibility. There is no evidence in the filings of share buybacks, special dividends, or large-scale capital returns. The absence of these items, combined with the thin equity cushion, suggests the company remains in a capital-accumulation phase rather than a capital-return phase. The evidence base does not include segment-level revenue splits, customer concentration, or contract renewal metrics, so the durability of the revenue base cannot be assessed from the filings alone. (source: 10-Q, period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/1496443/000168316826005583/xslF345X06/ownership.xml)

The company’s ownership filings on SEC EDGAR show multiple form amendments and beneficial ownership updates in June 2026, including PAYS 4, PAYS 4/A, and related submissions. These filings detail changes in share counts and beneficial ownership but do not disclose the economic rationale or strategic implications behind the transactions. The sheer volume of filings in a short window may indicate active insider activity, but the disclosures stop short of explaining whether this reflects routine administrative updates, equity incentives, or strategic repositioning. (source: SEC EDGAR filings index, https://www.sec.gov/edgar/browse/?CIK=1496443)

Paysign’s product pages are the primary public source for its business model and customer propositions, but they lack granular financial disclosures such as customer counts, average contract values, revenue per customer, or segment profitability. The absence of these metrics in the filings and product pages limits the ability to evaluate the scalability and defensibility of the business. Until the company files more detailed operating metrics, the commercial durability remains an open question. (source: product pages, https://paysign.com/solutions/pharmaceutical-services/; https://paysign.com/solutions/digital-banking-solutions/)